Cancer Genetics, Inc. and ApoCell Announce Partnership Focused on Transforming Cancer Profiling & Therapy Selection Leveraging Proprietary, High-Performance, Liquid Biopsy Platform for Rare Cell Capture and Detection
September 26, 2016 07:31 ET
|
Cancer Genetics, Inc.
The companies have entered into an agreement and partnership to offer biotech and pharmaceutical companies access to ApoCell’s ApoStream™ technology for the detection, isolation and enrichment of...
Cancer Genetics, Inc. to Present at Two Upcoming Investor Conferences During September
September 21, 2016 07:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers...
Cancer Genetics, Inc. Announces a Global Partnership with BARC Global Central Laboratory to Offer Comprehensive Clinical Trial and Companion Diagnostic Solutions for the Oncology Industry
September 20, 2016 07:30 ET
|
Cancer Genetics, Inc.
The companies have entered into an agreement to offer biotech and pharmaceutical companies access to BARC’s network of global central laboratories covering 7 locations in 2 hemispheres in...
Cancer Genetics Announces $5.5 Million Registered Direct Offering
September 09, 2016 07:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("Cancer Genetics" or the "Company"), a leader in enabling precision medicine for oncology through...
Cancer Genetics, Inc. to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 08, 2016 16:42 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers...
Cancer Genetics, Inc. Strengthens Position as a Leader in Myeloid Cancer Diagnosis and Management Receiving New York State Approval for Focus::Myeloid™, a Targeted NGS Panel for Improved Diagnosis, Risk Stratification, and Therapy Selection of Patients with Myeloid Cancers
August 17, 2016 07:30 ET
|
Cancer Genetics, Inc.
Focus::Myeloid™ can help clinicians and cancer centers improve the management and treatment of more than 275,000 patients in the U.S. currently living with myeloid malignancies Focus::Myeloid™ is a...
Cancer Genetics, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Updates
August 09, 2016 19:00 ET
|
Cancer Genetics, Inc.
Company Reports Quarterly Revenues of $7 million, an increase of 67% over the Second Quarter of 2015The Company’s Organic Growth Rate was 27% over Q1 and 18% over the Second Quarter of 2015, not...
Cancer Genetics to Report Second Quarter Earnings on Wednesday, August 10
August 01, 2016 17:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker Discovery and Testing for a Global Drug Development Program in Hematologic Cancers
July 18, 2016 09:29 ET
|
Cancer Genetics, Inc.
CGI will provide comprehensive, biomarker-based patient profiling using technologies such as next generation sequencing (NGS) to provide biomarker-driven insight regarding target...
Cancer Genetics, Inc. Receives New York State Approval for Focus::CLL™, a Unique NGS Panel for Chronic Lymphocytic Leukemia, Reinforcing the Company’s Market-Leading Position in the Diagnosis and Management of B-Cell Cancers
June 30, 2016 07:30 ET
|
Cancer Genetics, Inc.
Focus::CLL™ is the only CLIA-validated and NYS-approved NGS panel for CLL that offers information for patient risk stratification, disease management, and treatment selectionFocus::CLL™ addresses a...